Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV
Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.
Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972
Interviews
Focus On Asia
Data Analysis
R&D
• By
With no advances for decades, the STI could soon be facing two new antibiotic threats, while a third novel therapy has just entered the clinic.
• By
The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.
• By
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
• By
The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.
Business
• By
The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.
• By
The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.
• By
Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.
• By
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
Scrip Originals
• By
Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.
• By
BeOne could realize up to $950m under a deal with Royalty Pharma for its portion of sales from Amgen’s DLL3 inhibitor. Also, Novavax refinanced convertible debt, Kriya Therapeutics raised $313.3m in venture capital and Vaxxas garnered A$89.2m ($57.9m) in venture debt and cash.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent moves in the industry include new CEO hires at Artios Pharma, Rezo Therapeutics and Gubra, plus leadership changes at X4 Pharmaceuticals.